Prosight Management, LP Kal Vista Pharmaceuticals, Inc. Transaction History

Prosight Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$6.3 - $8.39 $2.4 Million - $3.2 Million	-381,667 Reduced 61.39%	240,000 $1.89 Million
Q4 2022 Feb 14, 2023	BUY	$4.2 - $14.24 $384,741 - $1.3 Million	91,605 Added 17.28%	621,667 $4.2 Million
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $2.86 Million - $4.89 Million	-290,690 Reduced 35.42%	530,062 $7.69 Million
Q2 2022 Aug 12, 2022	BUY	$8.16 - $15.1 $1.89 Million - $3.5 Million	231,482 Added 39.28%	820,752 $8.08 Million
Q1 2022 May 16, 2022	BUY	$11.2 - $16.97 $2.01 Million - $3.05 Million	179,650 Added 43.86%	589,270 $8.69 Million
Q4 2021 Feb 14, 2022	BUY	$12.36 - $18.28 $1.88 Million - $2.78 Million	152,229 Added 59.14%	409,620 $5.42 Million
Q3 2021 Nov 12, 2021	BUY	$17.11 - $24.49 $1.3 Million - $1.87 Million	76,220 Added 42.07%	257,391 $4.49 Million
Q2 2021 Aug 13, 2021	BUY	$23.12 - $29.91 $4.19 Million - $5.42 Million	181,171 New	181,171 $4.34 Million

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $220M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.